Aurobindo Pharma Limited has issued an official clarification regarding media reports suggesting that the company is closing in on a potential $5.5 billion acquisition of Zentiva.
The clarification, filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, states that while the company routinely explores strategic opportunities such as acquisitions and partnerships to strengthen its long-term growth, no binding agreement or definitive decision has been taken by the Board of Directors in connection with the rumored Zentiva deal.
The company emphasized that the media reports are premature and speculative, and investors should not rely on such information. Aurobindo Pharma also assured that in case of any concrete development that warrants disclosure under SEBI regulations, it will promptly make an official announcement to the stock exchanges.
With this clarification, Aurobindo Pharma reiterated its commitment to maintaining full compliance with SEBI disclosure requirements and ensuring transparency for its stakeholders.
